SCHEMBL16205996

SCHEMBL16205996

Cc1cccc(-n2nnn(C)c2=O)c1COc1cccc(-c2ccccc2)n1

nearest known ligand 0.36

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 3/20 0.36
HTR7 P34969 1/20 0.35
ALDH1A1 P00352 3/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CG P48736 1/20 0.33
PDE10A Q9Y233 4/20 0.32
GRM5 P41594 2/20 0.32
PKM P14618 1/20 0.32
FFAR1 O14842 1/20 0.32
TSHR P16473 1/20 0.31
MEN1 O00255 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
TP53 P04637 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16206095 0.93 HTR7 (0.34) HTR7
SCHEMBL16206108 0.92 MCL1 (0.33) GABRA5HTR7ALDH1A1PKM
SCHEMBL16205960 0.92 HTR7 (0.34) HTR7PDE10ARAB9A
SCHEMBL16205991 0.91 GABRA5 (0.35) GABRA5HTR7ALDH1A1GRM5RAB9A
SCHEMBL17614527 0.91 GRM2 (0.36) GABRA5HTR7ALDH1A1FFAR1RAB9A
SCHEMBL16206004 0.91 HTR7 (0.33) GABRA5HTR7ALDH1A1PKMRAB9A
SCHEMBL17614537 0.91 HTR7 (0.33) HTR7TP53
SCHEMBL17614531 0.90 CYP2A6 (0.39) GABRA5HTR7ALDH1A1PDE10AGRM5
SCHEMBL16205992 0.90 ALDH1A1 (0.36) HTR7ALDH1A1PDE10APKMTSHR
SCHEMBL17614571 0.89 GRM2 (0.35) HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2990404-B1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL CO (JP) 2020-05-27 EP disclosed
EP-2990404-B1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL CO (JP) 2020-05-27 EP disclosed
US-9867372-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-16 US disclosed
US-9867372-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-16 US disclosed
US-9867372-B2 Tetrazolinone compound and use of same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-01-16 US disclosed
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-03-24 US disclosed
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-03-24 US disclosed
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-03-24 US disclosed
EP-2990404-A1 TETRAZOLINONE COMPOUND AND USE OF SAME Sumitomo Chemical Company Limited (JP) 2016-03-02 EP disclosed
WO-2014175465-A1 TETRAZOLINONE COMPOUND AND USE OF SAME 住友化学株式会社 (JP) 2014-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160081339-A1 TETRAZOLINONE COMPOUND AND USE OF SAME MT-CO1, SOD1, MT-CO2 GABRA5 2741/4885HTR7 2834/4885ALDH1A1 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.